- |||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5468; Pts received HAIC of modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h), lenvatinib (8 or 12 mg once daily for body weight, 60 or ?60 kg), and tislelizumab (200 mg q3w)...4%), HAIC+Tisle+Regorafenib (5... The combination of HAIC with tislelizumab and lenvatinib represents a promising efficacy and manageable safety for uHCC pts with Vp4, which supplements the trial data for Vp4-HCC with real world outcomes.
- |||||||||| ETN101 / Etnova Therap
Preclinical antitumor efficacy of ETN101, a novel oral anticancer agent with Wnt/ () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5306; We developed ETN101, a monotherapy that targets VEGFR2 and modulates the TME with the same mechanism as the combination therapy. ETN101 also showed excellent efficacy in preclinical study and secured a broad safety margin relative to the effective dose.
- |||||||||| Comparison of checkpoint inhibitor () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5277;
Among ICI combinations, better survival and response rates were reported with sintilimab + bevacizumab, atezolizumab + bevacizumab, and camrelizumab + rivoceranib. Therefore, these regimens should be preferred for treatment of advanced HCC as first line therapy in patients who can tolerate these regimens.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib, gemcitabine, and oxaliplatin for 67 patients with fibrolamellar carcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5226; P=N/A Our retrospective study of high-risk FLC, most multiply relapsed, pretreated, stage 4 and unresectable, showed that a prolonged and meaningful clinical response and acceptable quality of life with a chance for curative surgery is possible for many young patients thought to be incurable. Prospective trials are needed to confirm these results.
- |||||||||| GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers. (Hall A; Poster Bd #: 163b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3916;
P2 Early-phase studies have demonstrated the efficacy of volrustomig (volru; anti-PD-1/CTLA-4 bispecific humanized IgG1 monoclonal antibody [mAb]) in patients (pts) with non-small-cell lung cancer (NSCLC) and renal cell carcinoma, and of rilvegostomig (rilve; anti-PD-1/TIGIT bispecific humanized IgG1 mAb) in pts with NSCLC, along with manageable safety profiles...Pts will be treated with volru as monotherapy or in combination with bevacizumab or lenvatinib...Pts will be treated with gemcitabine + cisplatin with either rilve or volru...The study is currently recruiting at sites in the US, Asia, and Europe. GEMINI-Hepatobiliary master protocol design.
- |||||||||| E7386 / Eisai, PRISM Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC). (Hall A; Poster Bd #: 309b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2140; P1 Study sites will include the United States, France, Republic of Korea, Japan, and Taiwan. As of February 5, 2024, 46 pts with HCC and 16 pts with EC have enrolled.
- |||||||||| Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. (Hall A; Poster Bd #: 303) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2129; P2 Although manageable, neutropenia emerged as a notable adverse effect. These findings underscore the potential of this combination as a therapeutic strategy for advanced solid tumors, warranting further clinical investigation.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
The molecular landscape of pembrolizumab and lenvatinib treatment in endometrial cancer. (Hall A; Poster Bd #: 483) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1924; Among TP53-mt patients, ARID1A-mt is associated with improved pembro-lenv survival but not in pembro alone. Our findings suggest a need to readdress when to use lenvatinib in TP53-mt patients and further explore genomic alterations that may promote treatment response to optimize use of this agent in endometrial cancer.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Outcomes of reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer. (Hall A; Poster Bd #: 459) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1901; In addition, those who received a lower starting dose experienced fewer dose reductions but no difference in dose discontinuation due to AE. Prospective studies of dose and schedule are needed to confirm these findings and define an optimal dosing strategy.
|